8-K: NeurAxis Reports Strong Q3 2024 Results with 40% Revenue Increase

NeurAxis, a medical technology company, announced a 40% increase in revenue for the third quarter of 2024, driven by strong demand for its IB-Stim product.

Summary

• NeurAxis reported a 40% increase in revenue for the third quarter of 2024, reaching $667 thousand compared to $477 thousand in the same period last year.
• The company's operating loss improved by 45% compared to the third quarter of 2023.
• Unit sales of the IB-Stim product grew by 50% in the third quarter.
• NeurAxis expanded its total covered lives to approximately 35 million, up from 4.5 million as of October 1, 2023.
• The company secured a $5.0 million capital investment to replace $3.2 million in committed funding.
• A new CPT Category I code for PENFS procedures will be effective January 1, 2026.
• The FDA cleared an expansion of the IB-Stim label to include patients aged 8-21 years and allow for up to 4 devices per patient.
• The company submitted its innovative rectal expulsion device (RED) product to the FDA for clearance.
• The net loss for the quarter was $1.8 million, a decrease of 80% compared to $8.6 million in the third quarter of 2023.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to significant revenue growth, improved operating loss, and successful expansion of insurance coverage and FDA clearances. The secured capital investment further strengthens the positive outlook.

Positives

• The company experienced a significant 40% increase in revenue year-over-year.
• Operating losses decreased by 45% compared to the same quarter last year.
• Unit sales of the IB-Stim product increased by 50% in the third quarter.
• The company has expanded insurance coverage to approximately 35 million lives.
• A new CPT Category I code for PENFS procedures was obtained.
• The FDA cleared an expansion of the IB-Stim label to include a broader age range and allow for more devices per patient.
• A $5.0 million capital investment was secured, strengthening the balance sheet.
• The net loss decreased by 80% compared to the third quarter of 2023.
• Gross profit increased by 39% due to higher sales volume.

Negatives

• The company still reported an operating loss of $1.7 million for the quarter.
• Cash on hand as of September 30, 2024 was $261 thousand.
• Cash used in operations for the nine months ended September 30, 2024 was $4.3 million, higher than the previous year due to costs of being a public company.
• The gross margin declined slightly by 50 basis points due to discounts given to patients without insurance coverage.

Risks

• The company's cash on hand is low at $261 thousand as of September 30, 2024, although a $5.0 million investment is expected to close soon.
• The company is still operating at a loss, although the loss has decreased significantly.
• The company's future success depends on continued expansion of insurance coverage and adoption of its technology.
• The company is subject to risks and uncertainties related to FDA approvals and clinical trials.

Future Outlook

Management is cautiously optimistic for FDA clearance of the RED device in the fourth quarter of 2024 and believes the company is well-positioned to execute its business plans for the foreseeable future due to recent financings.

Management Comments

• Brian Carrico, Chief Executive Officer of NeurAxis, commented, 'We are excited about our strong performance in the 3Q24, as revenues increased 40% year over year.'
• Brian Carrico also stated, 'Demand for our IB-Stim product is accelerating, as unit sales grew 50% in the third quarter.'
• He further added, 'Our commercialization, based on strong data publication leading to insurance coverage, is beginning to bear fruit.'

Industry Context

The announcement reflects a positive trend in the neuromodulation therapy market, with increasing adoption of non-pharmacological treatments for chronic conditions. The expansion of insurance coverage and FDA clearances are key drivers for growth in this sector.

Comparison to Industry Standards

• The 40% revenue growth is strong compared to many medical device companies in the early commercialization phase, although specific benchmarks vary widely.
• The 45% improvement in operating loss is a positive sign, but the company still needs to achieve profitability, which is common for companies in this stage.
• The expansion of covered lives to 35 million is a significant achievement, indicating successful market penetration compared to peers with similar technologies.
• The FDA clearance for expanded age range and device usage is a competitive advantage, as it broadens the potential patient base.
• Companies like Nevro Corp (NVRO) and Inspire Medical Systems (INSP) are established players in neuromodulation, but they focus on different applications, making direct comparisons challenging. However, NeurAxis's growth rate is competitive with these companies at similar stages of development.

Stakeholder Impact

• Shareholders will likely view the strong financial results and positive developments favorably.
• Employees may be encouraged by the company's growth and success.
• Patients will benefit from increased access to the IB-Stim therapy due to expanded insurance coverage.
• Payers will need to consider the cost-effectiveness of the IB-Stim therapy as coverage expands.

Next Steps

• The company will continue to focus on expanding insurance coverage and adoption of its IB-Stim therapy.
• The company is awaiting FDA clearance for its rectal expulsion device (RED) product.
• The company will continue clinical research in the pediatric space.
• The company will close the $5.0 million capital investment in mid-November 2024.

Key Dates

Keywords

NeurAxis, IB-Stim, PENFS, neuromodulation, medical technology, revenue, operating loss, FDA clearance, CPT code, insurance coverage